Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 6,236 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Weekly Assessment Clear all

Conditions: Diabetes Mellitus, Aging
Interventions: Motivational support, PALS - Physical activity for lifetime success; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 50 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Alzheimer's Disease
Interventions: Aerobic Exercise, Stretching; Behavioral
Lead sponsor: Jeff Burns, MD; Other
Eligibility: 55 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hepatitis C, Drug Use
Interventions: Rapid Treatment strategy, Usual Care (facilitated referral); Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 29 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Autism Spectrum Disorder
Interventions: Cognitive-Behavior Therapy, Treatment as Usual; Behavioral · Other
Lead sponsor: University of South Florida; Other
Eligibility: 16 Years to 21 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Breast Cancer, Cognitive Symptom
Interventions: Health Enhancement Program, Mindfulness-Based Stress Reduction; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years to 79 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Clostridium Difficile
Interventions: Probiotic, Placebo; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions: Capecitabine, Celecoxib, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Radiation Therapy, Stereotactic Radiosurgery, Therapeutic Conventional Surgery; Drug · Radiation · Other + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions: Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W); Drug
Lead sponsor: QuantumLeap Healthcare Collaborative; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2031
U.S. locations: 42
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more

Conditions: Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma, Childhood Glioblastoma, Childhood Malignant Glioma
Interventions: ATM Kinase Inhibitor AZD1390, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration; Drug · Procedure · Radiation + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 22 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: Obesity, Compensated Cirrhosis, Sarcopenia
Interventions: Continuous Energy Restriction (CER), Alternate Day Modified Fasting (ADMF), Group Health Education Sessions, Late Evening Snack, Physical activity, Self-monitoring, Remotely Supervised Exercise Sessions; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Mild to Moderate Alzheimer's Disease
Interventions: GV1001 Placebo, GV1001 0.56mg, GV1001 1.12mg; Drug
Lead sponsor: GemVax & Kael; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Adventura, Florida • Greenacres City, Florida • Miami, Florida + 8 more

Conditions: Neoplasm Malignant
Interventions: SAR442257; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Duarte, California • Miami, Florida • Rochester, Minnesota

Conditions: Pancreatic Cancer
Interventions: Walking Program; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pain, Chronic Pain, Physical Activity
Interventions: GetActive, Get Active with Fitbit; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Peripheral Neuropathy
Interventions: weightbearing exercise, nonweightbearing exercise, nonexercising control; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 40 Years to 90 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Child Abuse
Interventions: Assessment, Fostering Healthy Futures (FHF); Other · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 9 Years to 11 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Atrial Fibrillation
Interventions: Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux), Placebo (for warfarin), Avidin, Placebo (for avidin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 3,773 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 162
States / cities: Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 134 more

Conditions: Inflammatory Bowel Disease
Interventions: Bone Marrow Stromal Cell (BMSC) Infusion; Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity
Interventions: Evaluation of the Shape Up RI Campaign; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Cardiac Rehabilitation
Interventions: Activity Tracker; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Overweight and Obesity, Overweight Adolescents, Emotional Stress, Stress, Psychological, Eating Behavior
Interventions: Mindfulness-Based Weight Control (MBWC), Standard Behavioral Weight Control (SBWC); Behavioral
Lead sponsor: Kent State University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Kent, Ohio

Conditions: Anemia, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Drug Toxicity, Radiation Toxicity, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Interventions: External Beam Radiation Therapy, Cisplatin, Internal Radiation Therapy, Epoetin Alfa; Radiation · Drug · Biological
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Weight Loss, Anovulation, Amenorrhea, Infertility
Interventions: Commercial Weight Loss Program; Behavioral
Lead sponsor: Cornell University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Ithaca, New York

Conditions: Neoplasms, Breast
Interventions: lapatinib, carboplatin, trastuzumab, paclitaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 3
States / cities: La Jolla, California • Indianapolis, Indiana • Greensboro, North Carolina

Search by objective public record fields.

MY PALS: A Community-Based Physical Activity Support Program for Older Adults

Pilot Study of Aerobic Exercise in Early Alzheimer's Disease(AD)

HCV Seek, Test and Rapid Treatment for Young PWID

Treatment of Anxiety in Late Adolescents With Autism

MBSR During AI Therapy for Breast Cancer

Probiotics for Clostridium Difficile Infection in Older Adults

A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

OPTIMIzing muScle Preservation in paTients wIth Cirrhosis

GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Fatigue and Pancreas and Bile Duct Cancer Study

Integrating Mind-Body Skills With Physical Activity to Improve Physical and Emotional Outcomes in Patients With Chronic Pain

Effect of Weight-Bearing Exercise on People With Diabetes and Neuropathic Feet

Intervention Development and Pilot for Foster Care Youth

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

Bone Marrow Stromal Cells for Inflammatory Bowel Diseases

Evaluation of the Shape Up Rhode Island Campaign Study 5

Sustaining Physical Activity Following Cardiac Rehabilitation Completion

Healthy Eating, Activity and Reduction of Teen Stress

Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia

Evaluation of Ovarian Morphology and Function in Overweight Women During Weight Loss

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.